XFOR
X4 Pharmaceuticals, Inc.$4.01+0.13 (+3.35%)Prev Close$3.88·MCap$48.0M·P/E—·Vol440.8K·Yield—
▲
Buys (12M)
1
$250.0K
▼
Sells (12M)
1
$72.8K
◆
Net Activity
Net Buyer
$177.2K
●
Active Insiders
2
last 12 mo
Over the past 12 months, insider activity at X4 Pharmaceuticals, Inc. (XFOR) has been dominated by buying, with 1 insider purchase totaling $250.0K and 1 insider sale totaling $72.8K. The most recent insider transaction was by KIRSKE DAVID (officer: Chief Financial Officer), who sold $72.8K worth of shares on May 13, 2026. X4 Pharmaceuticals, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $48.0M.
XFOR Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| May 13, 2026 | KIRSKE DAVID | officer: Chief Financial Officer | Sell | 16,961 | $4.29 | $72.8K | 176,293 |
| Oct 23, 2025 | Craig Adam R | Executive Chairman | Buy | 86,206 | $2.90 | $250.0K0.8% OS | 0 |
| May 16, 2025 | Baldry Mark | Chief Commercial Officer | Buy | 1,032 | $2.48 | $2.6K | 0 |
| Feb 14, 2025 | Baldry Mark | Chief Commercial Officer | Buy | 35,050 | $0.55 | $19.3K | 129,173+37% |
| Jan 27, 2025 | Arbet-Engels Christophe | Chief Medical Officer | Sell | 11,624 | $0.45 | $5.3K | 14,207-45% |
| Jan 27, 2025 | Baldry Mark | Chief Commercial Officer | Sell | 29,159 | $0.45 | $13.2K | 94,123 |
| Jan 27, 2025 | DiBiase Mary | Chief Operating Officer | Sell | 22,258 | $0.45 | $10.1K | 490,980 |
| Jan 27, 2025 | Mostafa Adam S. | Chief Financial Officer | Sell | 74,773 | $0.45 | $33.9K0.7% OS | 0Exit |
| Jan 27, 2025 | Ragan Paula | President and CEO | Sell | 76,473 | $0.45 | $34.7K0.7% OS | 1,087,386 |
| Nov 19, 2024 | Ragan Paula | President and CEO | Sell | 31,897 | $0.39 | $12.6K | 993,919 |
| Oct 16, 2024 | Ragan Paula | President and CEO | Sell | 31,897 | $0.56 | $17.9K | 1,025,816 |
| Oct 8, 2024 | Baldry Mark | Chief Commercial Officer | Sell | 11,127 | $0.58 | $6.5K | 48,509 |
| Oct 8, 2024 | DiBiase Mary | Chief Operating Officer | Sell | 67,695 | $0.57 | $38.3K0.6% OS | 452,060 |
| Oct 8, 2024 | Mostafa Adam S. | Chief Financial Officer | Sell | 230,645 | $0.55 | $126.9K2.0% OS | 0Exit |
| Oct 8, 2024 | Ragan Paula | President and CEO | Sell | 239,436 | $0.55 | $131.5K2.1% OS | 1,057,713 |
| Oct 8, 2024 | Taveras Arthur | Chief Scientific Officer | Sell | 76,920 | $0.56 | $43.3K0.7% OS | 388,026 |
| Sep 11, 2024 | DiBiase Mary | Chief Operating Officer | Sell | 2,642 | $0.66 | $1.7K | 289,110 |
| Mar 11, 2024 | DiBiase Mary | Chief Operating Officer | Sell | 15,409 | $0.88 | $13.6K | 291,752 |
| Mar 11, 2024 | Mostafa Adam S. | Chief Financial Officer | Sell | 52,500 | $0.88 | $46.3K | 0Exit |
| Mar 11, 2024 | Ragan Paula | President and CEO | Sell | 49,678 | $0.88 | $43.9K | 765,068 |
| Mar 11, 2024 | Taveras Arthur | Chief Scientific Officer | Sell | 14,235 | $0.88 | $12.6K | 234,301 |
| Feb 12, 2024 | DiBiase Mary | Chief Operating Officer | Sell | 3,683 | $1.01 | $3.7K | 307,161 |
| Feb 12, 2024 | Mostafa Adam S. | Chief Financial Officer | Sell | 27,721 | $1.01 | $28.0K | 52,500-35% |
| Feb 12, 2024 | Ragan Paula | President and CEO | Sell | 21,695 | $1.01 | $21.9K | 814,746 |
| Feb 12, 2024 | Taveras Arthur | Chief Scientific Officer | Sell | 787 | $1.01 | $792.67 | 248,536 |
| Nov 3, 2023 | Baldry Mark | Chief Commercial Officer | Sell | 10,257 | $0.73 | $7.5K | 24,690-29% |
| Nov 3, 2023 | DiBiase Mary | Chief Operating Officer | Sell | 67,695 | $0.73 | $49.4K0.6% OS | 310,844 |
| Nov 3, 2023 | Mostafa Adam S. | Chief Financial Officer | Sell | 230,645 | $0.73 | $168.4K2.0% OS | 80,221-74% |
| Nov 3, 2023 | Ragan Paula | President and CEO | Sell | 239,437 | $0.76 | $181.6K2.1% OS | 876,347 |
| Nov 3, 2023 | Taveras Arthur | Chief Scientific Officer | Sell | 67,695 | $0.73 | $49.4K0.6% OS | 249,323 |
| Sep 12, 2023 | DiBiase Mary | Chief Operating Officer | Sell | 2,642 | $1.25 | $3.3K | 147,894 |
| Aug 22, 2023 | WYZGA MICHAEL S | Director | Buy | 25,000 | $1.20 | $29.9K | 76,667+48% |
| Aug 11, 2023 | Stewart Murray | Interim Chief Medical Officer | Sell | 130,056 | $1.06 | $137.9K1.1% OS | 146,504-47% |
| Jul 5, 2023 | DiBiase Mary | Chief Operating Officer | Sell | 464 | $1.89 | $876.96 | 150,536 |
| Jul 5, 2023 | Mostafa Adam S. | Chief Financial Officer | Sell | 2,641 | $1.89 | $5.0K | 80,221 |
| Jun 26, 2023 | DiBiase Mary | Chief Operating Officer | Sell | 857 | $1.93 | $1.7K | 151,000 |
| Jun 26, 2023 | Mostafa Adam S. | Chief Financial Officer | Sell | 5,417 | $1.93 | $10.5K | 82,862 |
| Jun 26, 2023 | Ragan Paula | President and CEO | Sell | 6,724 | $1.92 | $12.9K | 543,797 |
| Jun 16, 2023 | DiBiase Mary | Chief Operating Officer | Sell | 857 | $2.23 | $1.9K | 151,857 |
| Jun 16, 2023 | Mostafa Adam S. | Chief Financial Officer | Sell | 5,417 | $2.22 | $12.0K | 88,279 |
| Jun 16, 2023 | Ragan Paula | President and CEO | Sell | 6,724 | $2.23 | $15.0K | 550,521 |
| May 31, 2023 | Ragan Paula | President and CEO | Sell | 6,292 | $1.95 | $12.3K | 557,245 |
| Mar 13, 2023 | DiBiase Mary | Chief Operating Officer | Sell | 18,192 | $0.84 | $15.3K | 152,714 |
| Mar 13, 2023 | Mostafa Adam S. | Chief Financial Officer | Sell | 52,500 | $0.84 | $44.1K | 93,696-36% |
| Mar 13, 2023 | Ragan Paula | President and CEO | Sell | 49,678 | $0.84 | $41.7K | 563,537 |
| Mar 13, 2023 | Taveras Arthur | Chief Scientific Officer | Sell | 16,806 | $0.84 | $14.1K | 86,373 |
| Feb 15, 2023 | DiBiase Mary | Chief Operating Officer | Sell | 4,348 | $0.93 | $4.0K | 170,906 |
| Feb 15, 2023 | Mostafa Adam S. | Chief Financial Officer | Sell | 27,721 | $0.93 | $25.8K | 146,196 |
| Feb 15, 2023 | Ragan Paula | President and CEO | Sell | 21,695 | $0.93 | $20.2K | 613,215 |
| Feb 15, 2023 | Taveras Arthur | Chief Scientific Officer | Sell | 928 | $0.93 | $863.04 | 103,179 |
Showing 1–50 of 64
1 / 2
XFOR Insider Buying Activity
The following table shows recent insider purchases of X4 Pharmaceuticals, Inc. (XFOR) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Oct 23, 2025 | Craig Adam R | Executive Chairman | Buy | 86,206 | $2.90 | $250.0K0.8% OS | 0 |
| May 16, 2025 | Baldry Mark | Chief Commercial Officer | Buy | 1,032 | $2.48 | $2.6K | 0 |
| Feb 14, 2025 | Baldry Mark | Chief Commercial Officer | Buy | 35,050 | $0.55 | $19.3K | 129,173+37% |
| Aug 22, 2023 | WYZGA MICHAEL S | Director | Buy | 25,000 | $1.20 | $29.9K | 76,667+48% |
XFOR Insider Selling Activity
The following table shows recent insider sales of X4 Pharmaceuticals, Inc. (XFOR) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| May 13, 2026 | KIRSKE DAVID | officer: Chief Financial Officer | Sell | 16,961 | $4.29 | $72.8K | 176,293 |
| Jan 27, 2025 | Arbet-Engels Christophe | Chief Medical Officer | Sell | 11,624 | $0.45 | $5.3K | 14,207-45% |
| Jan 27, 2025 | Baldry Mark | Chief Commercial Officer | Sell | 29,159 | $0.45 | $13.2K | 94,123 |
| Jan 27, 2025 | DiBiase Mary | Chief Operating Officer | Sell | 22,258 | $0.45 | $10.1K | 490,980 |
| Jan 27, 2025 | Mostafa Adam S. | Chief Financial Officer | Sell | 74,773 | $0.45 | $33.9K0.7% OS | 0Exit |
| Jan 27, 2025 | Ragan Paula | President and CEO | Sell | 76,473 | $0.45 | $34.7K0.7% OS | 1,087,386 |
| Nov 19, 2024 | Ragan Paula | President and CEO | Sell | 31,897 | $0.39 | $12.6K | 993,919 |
| Oct 16, 2024 | Ragan Paula | President and CEO | Sell | 31,897 | $0.56 | $17.9K | 1,025,816 |
| Oct 8, 2024 | Baldry Mark | Chief Commercial Officer | Sell | 11,127 | $0.58 | $6.5K | 48,509 |
| Oct 8, 2024 | DiBiase Mary | Chief Operating Officer | Sell | 67,695 | $0.57 | $38.3K0.6% OS | 452,060 |
| Oct 8, 2024 | Mostafa Adam S. | Chief Financial Officer | Sell | 230,645 | $0.55 | $126.9K2.0% OS | 0Exit |
| Oct 8, 2024 | Ragan Paula | President and CEO | Sell | 239,436 | $0.55 | $131.5K2.1% OS | 1,057,713 |
| Oct 8, 2024 | Taveras Arthur | Chief Scientific Officer | Sell | 76,920 | $0.56 | $43.3K0.7% OS | 388,026 |
| Sep 11, 2024 | DiBiase Mary | Chief Operating Officer | Sell | 2,642 | $0.66 | $1.7K | 289,110 |
| Mar 11, 2024 | DiBiase Mary | Chief Operating Officer | Sell | 15,409 | $0.88 | $13.6K | 291,752 |
| Mar 11, 2024 | Mostafa Adam S. | Chief Financial Officer | Sell | 52,500 | $0.88 | $46.3K | 0Exit |
| Mar 11, 2024 | Ragan Paula | President and CEO | Sell | 49,678 | $0.88 | $43.9K | 765,068 |
| Mar 11, 2024 | Taveras Arthur | Chief Scientific Officer | Sell | 14,235 | $0.88 | $12.6K | 234,301 |
| Feb 12, 2024 | DiBiase Mary | Chief Operating Officer | Sell | 3,683 | $1.01 | $3.7K | 307,161 |
| Feb 12, 2024 | Mostafa Adam S. | Chief Financial Officer | Sell | 27,721 | $1.01 | $28.0K | 52,500-35% |
| Feb 12, 2024 | Ragan Paula | President and CEO | Sell | 21,695 | $1.01 | $21.9K | 814,746 |
| Feb 12, 2024 | Taveras Arthur | Chief Scientific Officer | Sell | 787 | $1.01 | $792.67 | 248,536 |
| Nov 3, 2023 | Baldry Mark | Chief Commercial Officer | Sell | 10,257 | $0.73 | $7.5K | 24,690-29% |
| Nov 3, 2023 | DiBiase Mary | Chief Operating Officer | Sell | 67,695 | $0.73 | $49.4K0.6% OS | 310,844 |
| Nov 3, 2023 | Mostafa Adam S. | Chief Financial Officer | Sell | 230,645 | $0.73 | $168.4K2.0% OS | 80,221-74% |
| Nov 3, 2023 | Ragan Paula | President and CEO | Sell | 239,437 | $0.76 | $181.6K2.1% OS | 876,347 |
| Nov 3, 2023 | Taveras Arthur | Chief Scientific Officer | Sell | 67,695 | $0.73 | $49.4K0.6% OS | 249,323 |
| Sep 12, 2023 | DiBiase Mary | Chief Operating Officer | Sell | 2,642 | $1.25 | $3.3K | 147,894 |
| Aug 11, 2023 | Stewart Murray | Interim Chief Medical Officer | Sell | 130,056 | $1.06 | $137.9K1.1% OS | 146,504-47% |
| Jul 5, 2023 | DiBiase Mary | Chief Operating Officer | Sell | 464 | $1.89 | $876.96 | 150,536 |
| Jul 5, 2023 | Mostafa Adam S. | Chief Financial Officer | Sell | 2,641 | $1.89 | $5.0K | 80,221 |
| Jun 26, 2023 | DiBiase Mary | Chief Operating Officer | Sell | 857 | $1.93 | $1.7K | 151,000 |
| Jun 26, 2023 | Mostafa Adam S. | Chief Financial Officer | Sell | 5,417 | $1.93 | $10.5K | 82,862 |
| Jun 26, 2023 | Ragan Paula | President and CEO | Sell | 6,724 | $1.92 | $12.9K | 543,797 |
| Jun 16, 2023 | DiBiase Mary | Chief Operating Officer | Sell | 857 | $2.23 | $1.9K | 151,857 |
| Jun 16, 2023 | Mostafa Adam S. | Chief Financial Officer | Sell | 5,417 | $2.22 | $12.0K | 88,279 |
| Jun 16, 2023 | Ragan Paula | President and CEO | Sell | 6,724 | $2.23 | $15.0K | 550,521 |
| May 31, 2023 | Ragan Paula | President and CEO | Sell | 6,292 | $1.95 | $12.3K | 557,245 |
| Mar 13, 2023 | DiBiase Mary | Chief Operating Officer | Sell | 18,192 | $0.84 | $15.3K | 152,714 |
| Mar 13, 2023 | Mostafa Adam S. | Chief Financial Officer | Sell | 52,500 | $0.84 | $44.1K | 93,696-36% |
| Mar 13, 2023 | Ragan Paula | President and CEO | Sell | 49,678 | $0.84 | $41.7K | 563,537 |
| Mar 13, 2023 | Taveras Arthur | Chief Scientific Officer | Sell | 16,806 | $0.84 | $14.1K | 86,373 |
| Feb 15, 2023 | DiBiase Mary | Chief Operating Officer | Sell | 4,348 | $0.93 | $4.0K | 170,906 |
| Feb 15, 2023 | Mostafa Adam S. | Chief Financial Officer | Sell | 27,721 | $0.93 | $25.8K | 146,196 |
| Feb 15, 2023 | Ragan Paula | President and CEO | Sell | 21,695 | $0.93 | $20.2K | 613,215 |
| Feb 15, 2023 | Taveras Arthur | Chief Scientific Officer | Sell | 928 | $0.93 | $863.04 | 103,179 |
XFOR Insiders
Similar Stocks to XFOR
VRTX
Vertex Pharmaceuticals Incorporated
$445.21+0.04%
$113.41B
REGN
Regeneron Pharmaceuticals, Inc.
$614.20+0.45%
$65.47B
ALNY
Alnylam Pharmaceuticals, Inc.
$283.35-2.09%
$40.46B
RVMD
Revolution Medicines, Inc.
$153.65+2.96%
$31.73B
UTHR
United Therapeutics Corporation
$542.43-0.54%
$23.12B
INSM
Insmed Incorporated
$98.28+1.64%
$20.41B
INCY
Incyte Corporation
$108.85+0.95%
$20.11B
MRNA
Moderna, Inc.
$50.18+1.06%
$18.89B